{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:47:47Z","timestamp":1785833267345,"version":"3.56.0"},"reference-count":31,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background\/Objective: Melanoma is an aggressive skin malignancy characterized by significant molecular heterogeneity. Among the molecular alterations identified in melanoma, BRAF mutations represent one of the most common genetic abnormalities and play an important role in activating the MAPK signaling pathway. BRAF mutation status has become clinically important because of its prognostic significance and implications for targeted therapy. This study aimed to evaluate the frequency of BRAF mutations and their associations with demographic, histopathological, and clinicopathological characteristics in melanoma patients at the only referral center for BRAF testing in Kosova, the Institute of Pathology, University Clinical Center of Kosova (UCCK). Methods: This retrospective study included 127 melanoma patients. Descriptive statistics, frequency analysis, Spearman\u2019s correlation and multivariable binary logistic regression analyses were performed to evaluate associations between BRAF mutation status and clinicopathological variables, including age, gender, Breslow thickness, histological type, ulceration, and anatomical localization. Results: BRAF mutation was identified in 76 of 127 melanoma patients (59.8%). The BRAF V600E\/V600E2\/V600D variants represented the predominant molecular subtype (75%). BRAF-positive melanoma was more frequently observed in younger patients and was significantly associated with increased Breslow thickness, nodular melanoma, ulceration, and trunk localization. Conclusions: BRAF mutations were highly prevalent in melanoma patients from Kosova and were associated with clinicopathological features of a more aggressive disease. The findings establish an important baseline for molecular epidemiology in the country and support the integration of routine BRAF testing into personalized melanoma management and future regional research.<\/jats:p>","DOI":"10.3390\/diseases14080278","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:02:19Z","timestamp":1785830539000},"page":"278","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association Between BRAF Mutation Status and Clinicopathological Features in Melanoma Patients in Kosova"],"prefix":"10.3390","volume":"14","author":[{"given":"Merita","family":"Hashani","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Prishtina, 10000 Pristina, Kosovo"},{"name":"Institute of Pathology, University Clinical Center of Kosova, 10000 Pristina, Kosovo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjeta","family":"Podrimaj-Bytyqi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Prishtina, 10000 Pristina, Kosovo"},{"name":"Institute of Pathology, University Clinical Center of Kosova, 10000 Pristina, Kosovo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"ref_1","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2024). Global Cancer Observatory: Cancer Today, International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.who.int\/today."},{"key":"ref_2","first-page":"e70090","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Saginala, K., Barsouk, A., Aluru, J.S., Rawla, P., and Barsouk, A. (2021). Epidemiology of Melanoma. Med. Sci., 9.","DOI":"10.3390\/medsci9040063"},{"key":"ref_4","first-page":"10732748241227340","article-title":"Global, Regional, and National Incidence Trend Analysis of Malignant Skin Melanoma Between 1990 and 2019, and Projections Until 2034","volume":"31","author":"Yuan","year":"2024","journal-title":"Cancer Control J. Moffitt Cancer Cent."},{"key":"ref_5","unstructured":"Barnhill, R.L., Bastian, B.C., Elder, D.E., Gerami, P., Cerroni, L., Busam, K.J., Lazar, A.J., Scolyer, R.A., Kazakov, D.V., and Massi, D. (2025). Melanocytic tumours. WHO Classification of Tumours Editorial Board. Skin Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The Genetic Evolution of Melanoma from Precursor Lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejcb.2014.01.002","article-title":"Metalloproteinases in melanoma","volume":"93","author":"Moro","year":"2014","journal-title":"Eur. J. Cell Biol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Yang, T.-T., Yu, S., Ke, C.-L.K., and Cheng, S.-T. (2023). The Genomic Landscape of Melanoma and Its Therapeutic Implications. Genes, 14.","DOI":"10.3390\/genes14051021"},{"key":"ref_11","first-page":"3728","article-title":"Mitogen-actived protein kinase activation is an early event in melanoma progression","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.critrevonc.2015.08.021","article-title":"Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma","volume":"96","author":"Carlino","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Castellani, G., Buccarelli, M., Arasi, M.B., Rossi, S., Pisanu, M.E., Bellenghi, M., Lintas, C., and Tabolacci, C. (2023). BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. Cancers, 15.","DOI":"10.3390\/cancers15164026"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/bjd.15436","article-title":"Beyond the BRAFV600E hotspot: Biology and clinical implications of rare BRAF gene mutations in melanoma patients","volume":"177","author":"Richtig","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/CMR.0000000000000628","article-title":"Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: A systemic review","volume":"30","author":"Nova","year":"2020","journal-title":"Melanoma Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8069","DOI":"10.18632\/oncotarget.14094","article-title":"Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry","volume":"8","author":"Bruno","year":"2017","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Elefanti, L., Zamuner, C., Del Fiore, P., Stagni, C., Pellegrini, S., Dall\u2019Olmo, L., Fabozzi, A., Senetta, R., Ribero, S., and Salmaso, R. (2021). The Molecular Landscape of Primary Acral Melanoma: A Multicenter Study of the Italian Melanoma Intergroup (IMI). Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22083826"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"114073","DOI":"10.1016\/j.ejca.2024.114073","article-title":"COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma","volume":"204","author":"Schadendorf","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_19","unstructured":"National Institute of Public Health of Kosova (2026). Report of Malignant Diseases for the Period January\u2013December 2025, National Institute of Public Health of Kosova, Department of the Health Information System. Available online: https:\/\/ikshpk.rks-gov.net\/publikimet\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_21","first-page":"134","article-title":"BRAF V600 Mutation Profile of Metastatic Melanoma in the Thrace Region of Turkey","volume":"34","author":"Can","year":"2018","journal-title":"Turk. Patoloji Derg."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"van der Kooij, M.K., Wetzels, M.J.A.L., Aarts, M.J.B., van den Berkmortel, F.W.P.J., Blank, C.U., Boers-Sonderen, M.J., Dierselhuis, M.P., de Groot, J.W.B., Hospers, G.A.P., and Piersma, D. (2020). Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma: A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response. Cancers, 12.","DOI":"10.3390\/cancers12082072"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_24","first-page":"472","article-title":"Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.23736\/S2784-8671.21.06958-3","article-title":"Histopathologic classification and prognostic factors of melanoma: A 2021 update","volume":"156","author":"Bobos","year":"2021","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Pizzichetta, M.A., Polesel, J., Sini, M.C., Manca, A., Simi, S., Paliogiannis, P., Pinzani, C., Corsetti, P., Canzonieri, V., and Astorino, S. (2025). Clinical, Histopathological, Dermoscopic Features, and BRAF, NRAS, and Cell Cycle Genes\u2019 Mutation Status in Cutaneous Melanoma. Cancers, 17.","DOI":"10.3390\/cancers17162688"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s00432-021-03562-1","article-title":"Multivariate analysis of prognostic factors in patients with nodular melanoma","volume":"147","author":"Susok","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jmoldx.2012.10.002","article-title":"Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma","volume":"15","author":"Greaves","year":"2013","journal-title":"J. Mol. Diagn. JMD"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/8\/278\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:40:00Z","timestamp":1785832800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/8\/278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["diseases14080278"],"URL":"https:\/\/doi.org\/10.3390\/diseases14080278","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]}}}